Background: The aim of our work was to determine the accuracy of 99mTc-HYNIC Tyr3 octreotide scintigraphy (TcOS) in detecting active disease in neuroendocrine tumors (NETs) based on embryological origin of the primary tumor (foregut, midgut or hindgut).
Methods: We analyzed retrospectively 45 studies (12 staging, 26 suspicion of recurrence, and 7 treatment response) belonging to 33 patients with histological confirmation of NETs. Whole body scan and a SPECT-CT were acquired 4 hours post-injection of 740 MBq of 99mTc-HYNIC Tyr3 octreotide. The studies were divided into 3 groups based on the embryological origin of primary tumor (foregut [group 1], midgut [group 2] and hindgut [group 3]). The accuracy of TcOS in each group was assessed, included chi-square analyses. The final diagnosis was established by histopathology or clinical/radiological follow-up greater than 6 months.
Results: The localization of the primary tumor per patient revealed that 58% were from the foregut, 30% from the midgut and 12% from the hindgut. In study-based analysis (45 studies), TcOS showed an overall sensitivity, specificity and accuracy of 95%, 92% and 93% respectively. The accuracy per studies for the groups 1, 2 and 3 were: 100%, 92% and 66% respectively, demonstrating a better detection of active disease in primary tumors from foregut and midgut compared to hindgut (P=0.02).
Conclusions: The accuracy of TcOS in the assessment of NETs seems to be better in tumors with foregut and midgut origin, showing a possible relationship between the embryological origin of NETs and detection of active disease by TcOS.